You may also notice worse symptoms after eating quickly, consuming carbonated drinks, eating fried foods, lying down soon after a meal, or eating close to a dose increase
Diabetes 63 , 23562368 (2014)
Should I stop tirzepatide if I develop cold sensitivity
12 The cardiovascular benefits of liraglutide were confirmed by the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial which reported lower cardiovascular mortality and morbidity (nonfatal myocardial infarction or stroke) in patients with type 2 diabetes treated with liraglutide 1.8 mg compared with placebo over a median follow up of 3.8 years
Clinical Evidence: Blood Pressure Reductions in GLP-1 Trials The LEADER trial, which followed over 9,000 people taking liraglutide (a similar GLP-1 drug), documented average systolic blood pressure drops of 23 mmHg within the first weeks of treatment
Areas of Scientific Interest GLP-1 receptor and incretin-pathway investigations Glucose-homeostasis and insulin-signaling research Appetite and satiety-signaling studies Adipose and energy-balance research models Metabolic-syndrome and obesity-related investigations Cardiometabolic and metabolic-regulation pathways Semaglutide continues to be investigated in metabolic, endocrine, and obesity-related research models focused on: Glucose regulation Energy-balance pathways Appetite-related signaling Caloric-intake modulation Metabolic-efficiency investigations For Laboratory and Research Use Only Not for human consumption or therapeutic use
